Study Official
Genmab · Xilis, Inc. · Bioeq GmbH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
44
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Study Official as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07859215 · Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian CancerGenmab · not yet recruiting · Ovarian Cancer · study director
- Ph3NCT07775287 · Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)Genmab · recruiting · Colorectal Cancer · study director
- Ph3NCT07702032 · Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)Genmab · recruiting · Left-sided Colorectal Cancer · study director
- Ph1NCT07695831 · A Phase 1 Trial of GEN1119 in Participants With Solid TumorsGenmab · recruiting · Solid Tumours · study director
- Ph3NCT07604766 · An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaGenmab · recruiting · Platinum-resistant Ovarian Cancer · study director
- Ph3NCT07564141 · Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerGenmab · recruiting · Platinum-Sensitive Ovarian Cancer, Ovarian Cancer · study director
- Ph2NCT07539311 · Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersGenmab · recruiting · Gastrointestinal Cancers · study director
- Ph1NCT07416123 · A Study of GEN1106 in Participants With Solid TumorsGenmab · recruiting · Solid Tumors, Urothelial Carcinoma · study director
- Ph1NCT07387068 · Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid TumorsGenmab · recruiting · Advanced Solid Tumors · study director
- Ph1NCT07384715 · First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)Genmab · recruiting · R/R AML, R/R HR-MDS, Acute Myeloid Leukemia · study director
- Ph2NCT07353957 · Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerGenmab · withdrawn · Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous · study director
- Ph2NCT07288177 · Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerGenmab · recruiting · Non-small Cell Lung Cancer (NSCLC) · study director
- Ph3NCT07226752 · A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaGenmab · active not recruiting · Diffuse Large B-Cell Lymphoma · study director
- Ph3NCT07225270 · Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet ChemotherapyGenmab · recruiting · Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC · study director
- Ph3NCT07166094 · Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerGenmab · recruiting · Endometrial Cancer, Recurrent or Progressive Endometrial Cancer · study director
- Ph2NCT06984328 · Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)Genmab · terminated · Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV) · study director
- Ph1/Ph2NCT06771921 · A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid TumorsGenmab · terminated · Malignant Solid Tumor · study director
- Ph1/Ph2NCT06685068 · A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid TumorsGenmab · terminated · Advanced Solid Tumor · study director
- Ph3NCT06635824 · Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Genmab · active not recruiting · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC · study director
- Ph3NCT06619236 · Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerGenmab · active not recruiting · Platinum-resistant Ovarian Cancer · study director
- Ph1NCT06573294 · Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid TumorsGenmab · terminated · Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors · study director
- Ph3NCT06525220 · A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Genmab · active not recruiting · Head and Neck Squamous Cell Carcinoma · study director
- Ph3NCT06496178 · A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Genmab · active not recruiting · Head and Neck Squamous Cell Carcinoma · study director
- Ph1/Ph2NCT06391775 · Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyGenmab · terminated · Malignant Solid Tumor · study director
- Ph1/Ph2NCT06171789 · PRO1107 in Patients With Advanced Solid TumorsGenmab · terminated · Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer · study director
- Ph1NCT06057038 · A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsGenmab · active not recruiting · Malignant Solid Tumor · study director
- Ph2NCT06046274 · GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerGenmab · withdrawn · Advanced Endometrial Cancer · study director
- Ph1/Ph2NCT06018129 · A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin LymphomaGenmab · terminated · Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma · study director
- Ph1/Ph2NCT05721222 · Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)Genmab · terminated · Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma · study director
- Ph1/Ph2NCT05579366 · Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Genmab · recruiting · High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma · study director
- Ph1/Ph2NCT05491317 · A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsGenmab · terminated · Non-CNS Tumor · study director
- N/ANCT05189171 · MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal CancerXilis, Inc. · completed · Colorectal Neoplasms · study director
- Ph1/Ph2NCT05180474 · GEN1047 for Solid Tumors - First in Human (FIH) TrialGenmab · terminated · Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms · study director
- Ph2NCT05117242 · Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerGenmab · terminated · Non Small Cell Lung Cancer Metastatic · study director
- Ph1NCT04937153 · GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesGenmab · completed · Solid Tumor · study director
- Ph1/Ph2NCT04824794 · GEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesGenmab · terminated · Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML) · study director
- Ph3NCT04595409 · A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque PsoriasisBioeq GmbH · completed · Plaque Psoriasis · study director
- Ph3NCT04522167 · Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular DegenerationBioeq GmbH · completed · Neovascular Age-related Macular Degeneration · study director
- Ph1/Ph2NCT04083599 · GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsGenmab · active not recruiting · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) · study director
- Ph1/Ph2NCT03917381 · GEN1046 Safety Trial in Patients With Malignant Solid TumorsGenmab · terminated · Solid Tumors · study director
- Ph1/Ph2NCT03625037 · First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaGenmab · active not recruiting · DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) · study director
- Ph1/Ph2NCT03526835 · A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsGenmab · recruiting · Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer · study director
- N/ANCT03281473 · Comparison of Positive End Expiratory Pressure Titration Methods in ARDS PatientsUniversity Hospital, Angers · unknown · Acute Respiratory Distress Syndrome · principal investigator
- Ph3NCT00332488 · Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 DiabetesMannkind Corporation · completed · Diabetes Mellitus, Type 2 · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.